The preparation of a number of cyclic imide 5-HT 1A receptor ligand derivatives has been described. Their structures were conformationally constrained by introducing rigid linkers containing unsaturated bonds or aromatic benzene rings. These compounds are expected to possess anxiolytic and antidepressant activity.
Introduction
Many compounds containing the arylpiperazine moiety posses high affinity and selectivity for 5-HT 1A receptors (e.g. buspirone, gepirone, tandospirone, BMY7378) and have been applied as anxiolytic and antidepressant drugs [1] [2] [3] [4] . Recent studies show that constraining the chain in the ligands can have a significant influence on their affinities towards serotonin receptors [5, 6] .
We have previously described the synthesis of select aryl-or heteroarylpiperazinylimide derivatives with constrained alkyl chains. This work is a continuation of our previous studies in search for compounds with anxiolytic and antidepressant activity among a group of long-chain arylpiperazine ligands [7] [8] [9] [10] [11] [12] [13] [14] [15] . 
Conclusions
In continuation of our research on cyclic imides with potential anxiolytic and antidepressive activity we have obtained thirty four new compounds belonging to the long-chain arylpiperazine ligand class. From the chemical and pharmacological point of view, these compounds are the basis for further research in the field of the potential drugs derived from cyclic imides.
Experimental

General
Melting points were determined in a capillary on an Electrothermal 9100 apparatus and are given uncorrected.
1 H-NMR spectra were recorded in DMSO-d 6 on a Bruker AVANCE DMX400 spectrometer operating at 400 MHz. The chemical shift values are expressed in ppm (parts per million) relatively to tetramethylsilane used as an internal standard and coupling constants J are given in Hz. The ESI MS were recorded on a Mariner Perspective-Biosystem instrument. Column chromatography was done using 0.05-0.2 mm Kieselgel (70-325 mesh ASTM, Merck). Reactions were monitored by TLC on 0.2 mm thick Kieselgel G plates with 254 nm fluorescent indicator (Merck), eluted with 9.8:0.2 or 9.5:0.5 chloroform-methanol. The imides A, C, D, F, G were obtained according to the methods described previously [13] [14] [15] . The imide E was commercially available (Aldrich). 
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General method for the preparation of the target compounds I-XXXIV: Synthesis of N-chloroalkenyl derivatives of the imides
The appropriate imide (0.01 mol) was dissolved in acetonitrile (30 mL, for C-E) or acetone (30 mL, for A-B, F-G), then anhydrous K 2 CO 3 (0.01 mol), a catalytic amount of KI and the appropriate linkercis-, or trans-1,4-dichloro-2-butene or 1,2-bis(chloromethyl)benzene (0.01 mol) -were added. The mixture was stirred at room temperature for 12-24 h. When the reaction was complete, as indicated by TLC, the mixture was filtered and the solvent was evaporated. The residue was purified by flash chromatography (eluent: chloroform-methanol 100:0.2).
Synthesis of aryl-and heteroarylpiperazinyl N-substituted imide derivatives
1-(2-Methoxyphenyl)piperazine or 1-(2-pyrimidinyl)piperazine (0.01 mol) were added to a mixture of N-chloroalkenylimide (0.01 mol), powdered anhydrous K 2 CO 3 (0.01 mol), and a catalytic amount of KI in acetone (30 mL) The reaction mixture was stirred at a room temperature for 24 h. After the reaction completion the inorganic residue was filtered off and the solvent was evaporated. The crude compound obtained was purified by flash chromatography (eluents: chloroform or chloroformmethanol 100:0.2). All new derivatives were converted into their corresponding hydrochlorides with ethereal HCl and recrystallized from methanol. [4-(2-methoxyphenyl) -2-en-1-yl}-4,7-dichloro-4,7-ethano-3a,4,9,9a- -4,7-ethano-3a,4,9, -4,7-ethano-3a,4,9,9a- 
4-{(2E)-
4-{(2Z)-[4-pirimidylpiperazin-1-yl]but-2-en-1-yl}-1-methoxy-4-azatricyclo
4-{(2Z)-[4-(2-methoxyphenyl)piperazin-1-yl]but-2-en-1-yl}-1-methoxy-4-azatricyclo
4-{(2Z)-[4-(2-methoxyphenyl)piperazin-1-yl]but-2-en-1-yl}-3,5-dioxo-4-azatricyclo
4-{(2E)-[4-pirimidylpiperazin-1-yl]but-2-en-1-yl}-3,5-dioxo-4-azatricyclo
4-{2-[4-(2-methoxyphenyl)-piperazin-1-yl]methylbenzyl}-3,5-dioxo-4-azatricyclo
4-[2-(4-pirimidylpiperazin-1-yl)methylbenzyl]-3,5-dioxo-4-azatricyclo
2-{(2Z)-[4-(2-methoxyphenyl)piperazin-1-yl]but-2-en-1-yl}-4,7-dichloro-4,7-ethano-3a,4,9,9a-tetrahydro-1H-dibenzo[fi]isoindole-1,3-(2H)-dione
2-{(2Z)-[4-pirimidylpiperazin-1-yl]but-2-en-1-yl}-4,7-dichloro-4,7-ethano-3a,4,9,9a-tetrahydro-1H-dibenzo[fi]isoindole-1,3-(2H)-dione
2-{(2E)-[4-(2-methoxyphenyl)piperazin-1-yl]but
2-{(2E)-[4-pirimidylpiperazin-1-yl]but-2-en-1-yl}-4,7-dichloro-4,7-ethano-3a,4,9,9a-tetrahydro-1H-dibenzo[fi]isoindole-1,3-(2H)-dione
2-{2-[4-(2-methoxyphenyl)-piperazin-1-yl]methylbenzyl}-4,7-dichloro-4,7-ethano-3a,4,9,9a-tetrahydro-1H-dibenzo[fi]isoindole-1,3-(2H)-dione
2-{(2Z)-[4-(2-methoxyphenyl)piperazin-1-yl]but-2-en-1-yl}-4-trifluoroacetyl
2-{(2Z)-[4-pirimidylpiperazin-1-yl]but-2-en-1-yl}-4-trifluoroacetyl
